Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

US Patent 11497770 · Granted Nov 15, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric antigen receptor therapies for treating solid tumors2025
Compositions and methods for treating cancer with anti-BCMA immunotherapy2025
Compositions and methods for treating cancer with anti-BCMA immunotherapy2025
Compositions and methods for treating cancer with anti-CD38 immunotherapy2025
Compositions and methods for treating cancer with anti-CD38 immunotherapy2025
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy2025
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy2025
Compositions and methods for treating cancer with DuoCARs2025
Compositions and methods for treating cancer with DuoCARs2025
FLT3-specific chimeric antigen receptors and methods using same2025
Method to treat cancer with engineered T-cells2025
Method to treat cancer with engineered T-cells2025